EPISODE · Feb 29, 2020 · 14 MIN
#5: Bacteria and immunotherapy
from Inflammatory Content · host Kellen Cavagnero, Ph.D.
Engineering bacteria to kill cancer cells… Sounds like science fiction, right? Well, it’s actually all science, no fiction! Sreyan Chowdhury and colleagues from Tal Danino’s lab at Columbia University describe this novel therapeutic approach in their recent Nature Medicine publication, “Programmable bacteria induce durable tumor regression and systemic antitumor immunity”.Paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688650/Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558487/Video: https://www.youtube.com/watch?v=fnpIIZrjMtM&t=18sTo help us spread science, please consider writing a review, sharing this episode with your friends and colleagues, or donating to support our work (Venmo @Kellen-Cavagnero). Please reach out to us via email ([email protected]) or Twitter (@KellenCavagnero) with any questions, comments, topic suggestions, etc.
What this episode covers
Engineering bacteria to kill cancer cells… Sounds like science fiction, right? Well, it’s actually all science, no fiction! Sreyan Chowdhury and colleagues from Tal Danino’s lab at Columbia University describe this novel therapeutic approach in their recent Nature Medicine publication, “Programmable bacteria induce durable tumor regression and systemic antitumor immunity”.Paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688650/Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558487/Video: https://www.youtube.com/watch?v=fnpIIZrjMtM&t=18sTo help us spread science, please consider writing a review, sharing this episode with your friends and colleagues, or donating to support our work (Venmo @Kellen-Cavagnero). Please reach out to us via email ([email protected]) or Twitter (@KellenCavagnero) with any questions, comments, topic suggestions, etc.
NOW PLAYING
#5: Bacteria and immunotherapy
No transcript for this episode yet
Similar Episodes
Apr 27, 2026 ·64m
Apr 24, 2026 ·69m
Apr 23, 2026 ·86m
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m